Literature DB >> 22521148

Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression.

Brian R Cornwell1, Giacomo Salvadore, Maura Furey, Craig A Marquardt, Nancy E Brutsche, Christian Grillon, Carlos A Zarate.   

Abstract

BACKGROUND: Clinical evidence that ketamine, a nonselective N-methyl-D-aspartate receptor (NMDAR) antagonist, has therapeutic effects within hours in people suffering from depression suggests that modulating glutamatergic neurotransmission is a fundamental step in alleviating the debilitating symptoms of mood disorders. Acutely, ketamine increases extracellular glutamate levels, neuronal excitability, and spontaneous γ oscillations, but it is unknown whether these effects are key to the mechanism of antidepressant action of ketamine.
METHODS: Twenty drug-free major depressive disorder patients received a single, open-label intravenous infusion of ketamine hydrochloride (.5 mg/kg). Magnetoencephalographic recordings were made approximately 3 days before and approximately 6.5 hours after the infusion, whereas patients passively received tactile stimulation to the right and left index fingers and also while they rested (eyes-closed). Antidepressant response was assessed by percentage change in Montgomery-Åsberg Depression Rating Scale scores.
RESULTS: Patients with robust improvements in depressive symptoms 230 min after infusion (responders) exhibited increased cortical excitability within this antidepressant response window. Specifically, we found that stimulus-evoked somatosensory cortical responses increase after infusion, relative to pretreatment responses in responders but not in treatment nonresponders. Spontaneous somatosensory cortical γ-band activity during rest did not change within the same timeframe after ketamine in either responders or nonresponders.
CONCLUSIONS: These findings suggest NMDAR antagonism does not lead directly to increased cortical excitability hours later and thus might not be sufficient for therapeutic effects of ketamine to take hold. Rather, increased cortical excitability as depressive symptoms improve is consistent with the hypothesis that enhanced non-NMDAR-mediated glutamatergic neurotransmission via synaptic potentiation is central to the antidepressant effect of ketamine.
Copyright © 2012 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22521148      PMCID: PMC3408548          DOI: 10.1016/j.biopsych.2012.03.029

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  53 in total

1.  Increase in high frequency EEG activity explains the poor performance of EEG spectral entropy monitor during S-ketamine anesthesia.

Authors:  A Maksimow; M Särkelä; J W Långsjö; E Salmi; K K Kaisti; A Yli-Hankala; S Hinkka-Yli-Salomäki; H Scheinin; S K Jääskeläinen
Journal:  Clin Neurophysiol       Date:  2006-06-27       Impact factor: 3.708

2.  Single- and multiple-dose pharmacokinetics of riluzole in white subjects.

Authors:  A Le Liboux; P Lefebvre; Y Le Roux; P Truffinet; M Aubeneau; S Kirkesseli; G Montay
Journal:  J Clin Pharmacol       Date:  1997-09       Impact factor: 3.126

3.  Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

Authors:  B Moghaddam; B Adams; A Verma; D Daly
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

4.  Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression.

Authors:  P V Choudary; M Molnar; S J Evans; H Tomita; J Z Li; M P Vawter; R M Myers; W E Bunney; H Akil; S J Watson; E G Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-17       Impact factor: 11.205

5.  Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression.

Authors:  R Bernard; I A Kerman; R C Thompson; E G Jones; W E Bunney; J D Barchas; A F Schatzberg; R M Myers; H Akil; S J Watson
Journal:  Mol Psychiatry       Date:  2010-04-13       Impact factor: 15.992

6.  Magnetoencephalographic gamma power reduction in patients with schizophrenia during resting condition.

Authors:  Lindsay Rutter; Frederick W Carver; Tom Holroyd; Sreenivasan Rajamoni Nadar; Judy Mitchell-Francis; Jose Apud; Daniel R Weinberger; Richard Coppola
Journal:  Hum Brain Mapp       Date:  2009-10       Impact factor: 5.038

7.  An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Authors:  Sheldon H Preskorn; Bryan Baker; Sheela Kolluri; Frank S Menniti; Michael Krams; Jaren W Landen
Journal:  J Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.153

8.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

9.  NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.

Authors:  Anita E Autry; Megumi Adachi; Elena Nosyreva; Elisa S Na; Maarten F Los; Peng-fei Cheng; Ege T Kavalali; Lisa M Monteggia
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

10.  The functional consequences of cortical circuit abnormalities on gamma oscillations in schizophrenia: insights from computational modeling.

Authors:  Kevin M Spencer
Journal:  Front Hum Neurosci       Date:  2009-10-20       Impact factor: 3.169

View more
  68 in total

Review 1.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 2.  Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.

Authors:  Chadi G Abdallah; Lynnette A Averill; John H Krystal
Journal:  Ann N Y Acad Sci       Date:  2015-02-27       Impact factor: 5.691

Review 3.  Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Authors:  Mark J Niciu; Ioline D Henter; David A Luckenbaugh; Carlos A Zarate; Dennis S Charney
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

4.  Rapid Antidepressant Action and Restoration of Excitatory Synaptic Strength After Chronic Stress by Negative Modulators of Alpha5-Containing GABAA Receptors.

Authors:  Jonathan Fischell; Adam M Van Dyke; Mark D Kvarta; Tara A LeGates; Scott M Thompson
Journal:  Neuropsychopharmacology       Date:  2015-04-22       Impact factor: 7.853

5.  Veterans with PTSD demonstrate amygdala hyperactivity while viewing threatening faces: A MEG study.

Authors:  Amy Badura-Brack; Timothy J McDermott; Elizabeth Heinrichs-Graham; Tara J Ryan; Maya M Khanna; Daniel S Pine; Yair Bar-Haim; Tony W Wilson
Journal:  Biol Psychol       Date:  2018-01-05       Impact factor: 3.251

6.  Magnetoencephalographic Correlates of Suicidal Ideation in Major Depression.

Authors:  Jessica R Gilbert; Elizabeth D Ballard; Christina S Galiano; Allison C Nugent; Carlos A Zarate
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2019-12-03

Review 7.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

Review 8.  Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors:  Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal:  Behav Brain Res       Date:  2020-02-13       Impact factor: 3.332

9.  Modulation of motor cortex excitability predicts antidepressant response to prefrontal cortex repetitive transcranial magnetic stimulation.

Authors:  Albino J Oliveira-Maia; Daniel Press; Alvaro Pascual-Leone
Journal:  Brain Stimul       Date:  2017-03-31       Impact factor: 8.955

10.  Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism.

Authors:  Valentina Gigliucci; Grainne O'Dowd; Sheena Casey; Danielle Egan; Sinead Gibney; Andrew Harkin
Journal:  Psychopharmacology (Berl)       Date:  2013-03-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.